Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 18/20 | 0.85 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25063900 | 1.00 | STING1 (0.85) | STING1LMNA | |
| SCHEMBL26351022 | 1.00 | STING1 (0.85) | STING1LMNA | |
| SCHEMBL25063904 | 0.94 | STING1 (0.78) | STING1 | |
| SCHEMBL22334110 | 0.90 | STING1 (1.00) | STING1 | |
| SCHEMBL22434473 | 0.90 | STING1 (1.00) | STING1 | |
| SCHEMBL22334105 | 0.90 | STING1 (1.00) | STING1 | |
| SCHEMBL24967640 | 0.90 | STING1 (1.00) | STING1 | |
| SCHEMBL23477351 | 0.90 | STING1 (1.00) | STING1 | |
| SCHEMBL21532129 | 0.90 | STING1 (1.00) | STING1 | |
| SCHEMBL23800770 | 0.90 | STING1 (1.00) | STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729068-A1 | LENTIVIRAL VECTOR-BASED IMMUNOTHERAPY OF PROSTATE TUMORS | Theravectys (FR) | 2026-04-22 | — | — | EP | claimed |
| EP-4309739-B1 | CORE/SHELL STRUCTURE PLATFORM FOR IMMUNOTHERAPY | METHODIST HOSPITAL (US) | 2026-04-08 | — | — | EP | claimed |
| EP-3816176-B1 | HYDRATE CRYSTAL OF 3',3'-CGAMP | YAMASA CORP (JP) | 2026-03-04 | — | — | EP | claimed |
| US-12545903-B2 | Polypeptide assemblies and methods for the production thereof | UNIVERSITY OF WASHINGTON (US) | 2026-02-10 | — | — | US | claimed |
| US-20260034159-A1 | METHODS FOR PRODUCING CYCLIC DINUCLEOTIDES | ALDEVRON LLC (US) | 2026-02-05 | — | — | US | claimed |
| US-12533415-B2 | Core/shell structure platform for immunotherapy | THE METHODIST HOSPITAL (US) | 2026-01-27 | — | — | US | claimed |
| US-20250387425-A1 | NOVEL PERSONAL NEOANTIGEN VACCINES AND MARKERS | ANDA BIOLOGY MEDICINE DEV SHENZHEN CO LTD (CN) | 2025-12-25 | — | — | US | claimed |
| US-20250381256-A1 | SUBLINGUAL NANOFIBER VACCINES AND METHODS OF MAKING AND USING SAME | UNIV DUKE (US) | 2025-12-18 | — | — | US | claimed |
| WO-2025242657-A1 | LIPOPEPTIDE BUILDING BLOCKS AND AGGREGATES | SHAPE BIOPHARMACEUTICALS AG (CH) | 2025-11-27 | — | — | WO | claimed |
| US-20250282871-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | TIANJIN LIPOGEN TECH CO LTD (CN) | 2025-09-11 | — | — | US | claimed |
| WO-2022215079-A1 | NANOVACCINES FOR TREATMENT OF VIRAL DISEASES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2022-10-13 | — | — | WO | claimed |
| US-20220305103-A1 | CORE/SHELL STRUCTURE PLATFORM FOR IMMUNOTHERAPY | THE METHODIST HOSPITAL | 2022-09-29 | — | — | US | claimed |
| US-20220305048-A1 | USE OF HEPARIN TO PROMOTE TYPE 1 INTERFERON SIGNALING | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-09-29 | — | — | US | claimed |
| WO-2022195427-A1 | ADJUVANT FOR VACCINE DEVELOPMENT | SHEN HAIFA (US) | 2022-09-22 | — | — | WO | claimed |
| US-11396524-B2 | Hydrate crystal of 3′,3′-cGAMP | YAMASA CORPORATION (JP) | 2022-07-26 | — | — | US | claimed |
| WO-2022118043-A1 | NOVEL PROTEIN-LIGAND COMPLEX | ENARA BIO LIMITED (GB) | 2022-06-09 | — | — | WO | claimed |
| EP-4008344-A1 | CORE/SHELL STRUCTURE PLATFORM FOR IMMUNOTHERAPY | The Methodist Hospital (US) | 2022-06-08 | — | — | EP | claimed |
| WO-2022103927-A1 | IMMUNOGENIC COMPOSITIONS FOR CORONAVIRUSES | SHAPE BIOPHARMACEUTICALS INC. (US) | 2022-05-19 | — | — | WO | claimed |
| US-20220111029-A1 | POLYMERIC NANOVACCINES AND USES THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2022-04-14 | — | — | US | claimed |
| WO-2022032043-A1 | DENDRITIC CELL ACTIVATING THERAPY AS AN ADJUNCT TO RADIATION THERAPY | MONTEFIORE MEDICAL CENTER (US) | 2022-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533415-B2 | Core/shell structure platform for immunotherapy | PHOSPHO1, MYD88, PCTP | STING1 15/4885LMNA 454/4885 |
| US-11396524-B2 | Hydrate crystal of 3′,3′-cGAMP | CGAS, GMPS, IAPP | STING1 11/4885LMNA 3712/4885 |
| US-20250387425-A1 | NOVEL PERSONAL NEOANTIGEN VACCINES AND MARKERS | PPP1R15A, STING1, PPP1R15B | STING1 2/4885LMNA 3608/4885 |
| US-20220305048-A1 | USE OF HEPARIN TO PROMOTE TYPE 1 INTERFERON SIGNALING | IFNAR1, IFNG, STAT1 | STING1 5/4885LMNA 4309/4885 |
| US-20260034159-A1 | METHODS FOR PRODUCING CYCLIC DINUCLEOTIDES | CGAS, STING1, IFNG | STING1 2/4885LMNA 3885/4885 |
| US-12545903-B2 | Polypeptide assemblies and methods for the production thereof | PICALM, PHAX, NSF | STING1 1387/4885LMNA 1937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.